BioCentury
ARTICLE | Company News

FDA approves Medicines Co.'s Kengreal

June 23, 2015 1:38 AM UTC

FDA approved Kengreal cangrelor from The Medicines Co. (NASDAQ:MDCO) as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural thrombotic events including myocardial infarction (MI), stent thrombosis and repeat coronary revascularization. Kengreal is indicated for patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

The Medicines Co. expects to launch the drug in July. The company declined to disclose a price for the reversible purinergic receptor P2Y G protein-coupled 12 ( P2RY12; P2Y12) antagonist. ...